MERCK & CO. INC. (6MK.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:6MK - US58933Y1055 - Common Stock
6MK.DE Key Statistics, Chart & Performance
The current stock price of 6MK.DE is 87.4 EUR. In the past month the price increased by 18.14%. In the past year, price decreased by -11.45%.
6MK.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.36 | 209.67B | ||
| 1SAN.MI | SANOFI | 11.36 | 209.67B | ||
| SAN.PA | SANOFI | 11.27 | 208.02B | ||
| MRK.DE | MERCK KGAA | 14.06 | 52.13B | ||
| UCB.BR | UCB SA | 37.35 | 46.64B | ||
| UNC.DE | UCB SA | 37.8 | 47.21B | ||
| BAYN.DE | BAYER AG-REG | 6.41 | 33.65B | ||
| 1BAYN.MI | BAYER AG-REG | 6.32 | 33.17B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.11 | 10.34B | ||
| IPN.PA | IPSEN | 11.86 | 10.21B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 101.92 | 9.44B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 18.49 | 7.90B |
Related stock screener links
About 6MK.DE
Company Profile
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Company Info
MERCK & CO. INC.
126 East Lincoln Avenue, P.O. Box 2000
Rahway NEW JERSEY US
Employees: 75000
Phone: 19087404000
MERCK & CO. INC. / 6MK.DE FAQ
Can you describe the business of MERCK & CO. INC.?
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
What is the stock price of MERCK & CO. INC. today?
The current stock price of 6MK.DE is 87.4 EUR. The price increased by 0.92% in the last trading session.
Does 6MK stock pay dividends?
MERCK & CO. INC. (6MK.DE) has a dividend yield of 3.25%. The yearly dividend amount is currently 2.68.
How is the ChartMill rating for MERCK & CO. INC.?
6MK.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about MERCK & CO. INC. (6MK.DE) stock?
33 analysts have analysed 6MK.DE and the average price target is 89.41 EUR. This implies a price increase of 2.3% is expected in the next year compared to the current price of 87.4.
Is MERCK & CO. INC. (6MK.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 6MK.DE.
When does MERCK & CO. INC. (6MK.DE) report earnings?
MERCK & CO. INC. (6MK.DE) will report earnings on 2026-02-03, after the market close.
6MK.DE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to 6MK.DE. When comparing the yearly performance of all stocks, 6MK.DE turns out to be only a medium performer in the overall market: it outperformed 52.92% of all stocks.
6MK.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 6MK.DE. 6MK.DE scores excellent on profitability, but there are some minor concerns on its financial health.
6MK.DE Financial Highlights
Over the last trailing twelve months 6MK.DE reported a non-GAAP Earnings per Share(EPS) of 7.59. The EPS increased by 48.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.63% | ||
| ROA | 14.69% | ||
| ROE | 36.71% | ||
| Debt/Equity | 0.77 |
6MK.DE Forecast & Estimates
33 analysts have analysed 6MK.DE and the average price target is 89.41 EUR. This implies a price increase of 2.3% is expected in the next year compared to the current price of 87.4.
For the next year, analysts expect an EPS growth of 18.21% and a revenue growth 1.08% for 6MK.DE